Explanipedia

Targeting peptide antigens using a multiallelic MHC I-binding system Open

Haotian Du, Leena Mallik, Daniel Hwang, Yi Sun, Chengzi I. Kaku , et al. · 2024

Characteristics and Functions of Infection-enhancing Antibodies to the N-terminal Domain of SARS-CoV-2 Open

Ruth I. Connor, Mrunal Sakharkar, Garrett Rappazzo, Chengzi I. Kaku, Nicholas C. Curtis , et al. · 2024

Background: Fcγ-receptor (FcγR)-independent enhancement of SARS-CoV-2 infection mediated by N-terminal domain (NTD)-binding monoclonal antibodies (mAbs) has been observed in vitro, but the functional significance of these antibodies in viv…

Characteristics and functions of infection-enhancing antibodies to the N-terminal domain of SARS-CoV-2 Open

Ruth I. Connor, Mrunal Sakharkar, C. Garrett Rappazzo, Chengzi I. Kaku, Nicholas C. Curtis , et al. · 2023

Characterization of functional antibody responses to the N-terminal domain (NTD) of the SARS-CoV-2 spike (S) protein has included identification of both potent neutralizing activity and putative enhancement of infection. Fcγ-receptor (FcγR…

Evolution of antibody immunity following Omicron BA.1 breakthrough infection Open

Chengzi I. Kaku, Tyler N. Starr, Pan-Pan Zhou, Haley L. Dugan, Paul Khalifé , et al. · 2023

longitudinal BA.1 breakthrough antibody dataset Open

Chengzi I. Kaku · 2023

Characterization of all antibodies isolated at the late time point following BA.1 breakthrough infection.

longitudinal BA.1 breakthrough antibody dataset Open

Chengzi I. Kaku · 2023

Characterization of all antibodies isolated at the late time point following BA.1 breakthrough infection.

Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers Open

Peter Schmidt, Kristin Narayan, Yong Li, Chengzi I. Kaku, Michael E. Brown , et al. · 2023

Multiple studies of vaccinated and convalescent cohorts have demonstrated that serum neutralizing antibody (nAb) titers correlate with protection against coronavirus disease 2019 (COVID-19). However, the induction of multiple layers of imm…

Evolution of antibody immunity following Omicron BA.1 breakthrough infection Open

Chengzi I. Kaku · 2023

Longitudinal characterization of monoclonal antibodies isolated following BA.1 breakthrough infection in mRNA-vaccinated donors.

Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19 Open

Elizabeth E. Zumbrun, Chengzi I. Kaku, Lukas Dillinger, Samantha E. Zak, Ana I. Kuehne , et al. · 2022

Adintrevimab is a human immunoglobulin G1 monoclonal antibody engineered to have broad neutralization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and other SARS-like coronaviruses with pandemic potential. …

Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers Open

Peter Schmidt, Kristin Narayan, Yong Li, Chengzi I. Kaku, Michael E. Brown , et al. · 2022

Multiple studies of vaccinated and convalescent cohorts have demonstrated that serum neutralizing antibody (nAb) titers correlate with protection against COVID-19. However, the induction of multiple layers of immunity following SARS-CoV-2 …

Evolution of antibody immunity following Omicron BA.1 breakthrough infection Open

Chengzi I. Kaku, Tyler N. Starr, Pan-Pan Zhou, Haley L. Dugan, Paul Khalifé , et al. · 2022

Understanding the evolution of antibody immunity following heterologous SAR-CoV-2 breakthrough infection will inform the development of next-generation vaccines. Here, we tracked SARS-CoV-2 receptor binding domain (RBD)-specific antibody r…

Human antibodies to SARS-CoV-2 with a recurring YYDRxG motif retain binding and neutralization to variants of concern including Omicron Open

Hejun Liu, Chengzi I. Kaku, Ge Song, Meng Yuan, Raiees Andrabi , et al. · 2022

A broad and potent neutralization epitope in SARS-related coronaviruses Open

Meng Yuan, Xueyong Zhu, Wanting He, Pan-Pan Zhou, Chengzi I. Kaku , et al. · 2022

Many neutralizing antibodies (nAbs) elicited to ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through natural infection and vaccination have reduced effectiveness to SARS-CoV-2 variants. Here, we show that therapeu…

Recall of preexisting cross-reactive B cell memory after Omicron BA.1 breakthrough infection Open

Chengzi I. Kaku, Alan Bergeron, Clas Ahlm, Johan Normark, Mrunal Sakharkar , et al. · 2022

Understanding immune responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection will facilitate the development of next-generation vaccines. Here, we profiled spike (S)–specific B cell responses aft…

Recall of pre-existing cross-reactive B cell memory following Omicron breakthrough infection Open

Chengzi I. Kaku, Alan Bergeron, Clas Ahlm, Johan Normark, Mrunal Sakharkar , et al. · 2022

Understanding immune responses following SARS-CoV-2 breakthrough infection will facilitate the development of next-generation vaccines. Here, we profiled spike (S)-specific B cell responses following Omicron/BA.1 infection in mRNA-vaccinat…

A broad and potent neutralization epitope in SARS-related coronaviruses Open

Meng Yuan, Xueyong Zhu, Wanting He, Pan-Pan Zhou, Chengzi I. Kaku , et al. · 2022

Many neutralizing antibodies (nAbs) elicited to ancestral SARS-CoV-2 through natural infection and vaccination generally have reduced effectiveness to SARS-CoV-2 variants. Here we show therapeutic antibody ADG20 is able to neutralize all S…

Broad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination Open

Chengzi I. Kaku, Elizabeth Champney, Johan Normark, Marina García, Carl E. Johnson , et al. · 2022

Heterologous prime-boost immunization strategies have the potential to augment COVID-19 vaccine efficacy. We longitudinally profiled severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)–specific serological and memory B c…

A recurring YYDRxG pattern in broadly neutralizing antibodies to a conserved site on SARS-CoV-2, variants of concern, and related viruses Open

Hejun Liu, Chengzi I. Kaku, Ge Song, Meng Yuan, Raiees Andrabi , et al. · 2021

Studying the antibody response to SARS-CoV-2 informs on how the human immune system can respond to antigenic variants as well as other SARS-related viruses. Here, we structurally and functionally characterized a potent human antibody ADI-6…

Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination Open

Chengzi I. Kaku, Elizabeth Champney, Johan Normark, Carl E. Johnson, Clas Ahlm , et al. · 2021

Heterologous prime-boost immunization strategies have the potential to augment COVID-19 vaccine efficacy and address ongoing vaccine supply challenges. Here, we longitudinally profiled SARS-CoV-2 spike (S)-specific serological and memory B…

Revisiting an IgG Fc Loss-of-Function Experiment: the Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity Open

Benjamin S. Goldberg, Chengzi I. Kaku, Jérémy Dufloo, Timothée Bruel, Olivier Schwartz , et al. · 2021

Given the suboptimal outcome of VRC01 antibody-mediated prevention of HIV-1 infection in its first field trial, means to improve diverse antiviral activities in vivo have renewed importance. This work revisits a loss-of-function experiment…

Prolonged evolution of the human B cell response to SARS-CoV-2 infection Open

Mrunal Sakharkar, C. Garrett Rappazzo, Wendy Wieland‐Alter, Ching‐Lin Hsieh, Daniel Wrapp , et al. · 2021

A comprehensive understanding of the kinetics and evolution of the human B cell response to SARS-CoV-2 infection will facilitate the development of next-generation vaccines and therapies. Here, we longitudinally profiled this response in m…

Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody Open

C. Garrett Rappazzo, Longping V. Tse, Chengzi I. Kaku, Daniel Wrapp, Mrunal Sakharkar , et al. · 2021

The recurrent zoonotic spillover of coronaviruses (CoVs) into the human population underscores the need for broadly active countermeasures. We employed a directed evolution approach to engineer three SARS-CoV-2 antibodies for enhanced neut…

Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody Open

C. Garrett Rappazzo, Longping V. Tse, Chengzi I. Kaku, Daniel Wrapp, Mrunal Sakharkar , et al. · 2021

Targeting sarbecoviruses As we continue to battle the COVID-19 pandemic, we must confront the possibility of new pathogenic coronaviruses emerging in humans in the future. With this in mind, Rappazzo et al. isolated antibodies from a survi…

An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19 Open

C. Garrett Rappazzo, Longping V. Tse, Chengzi I. Kaku, Daniel Wrapp, Mrunal Sakharkar , et al. · 2020

The recurrent zoonotic spillover of coronaviruses (CoVs) into the human population underscores the need for broadly active countermeasures. Here, we employed a directed evolution approach to engineer three SARS-CoV-2 antibodies for enhance…

Chengzi I. Kaku YOU? Author Swipe